Skip to main content

Main menu

  • About
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
    • News and Stories
    • Careers
  • Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
      • Other Research Focus Areas
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Dilawri Cardiovascular Institute
      • Djavad Mowafaghian Centre for Brain Health
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
    • Research Cores
      • Clinical Trials Platform
      • VCH-VCHRI AI Hub
      • Indigenous Health Research Unit
    • Researcher Directory
    • Events and Workshops
    • Participate in Research
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Research Development
      • Awards and Funding
      • Research Facilitation
      • Grant Management
      • Learning and Development
    • Contracts and Compliance
      • Contract Facilitation at VCHRI
      • Operational Approval
      • Research Privacy
      • Clinical Trials Administration
    • Research Support
      • Communications and Media Relations
      • Financial Policies and Procedures
      • VCH-VCHRI AI Hub
    • Find a Study
    • Indigenous Research
  • Clinical Trials
    • Clinical Trials Platform
      • Phase 1 Clinical Trials Research Unit
      • Hematology Research Unit
      • Clinical Research Unit
    • Find a Study
    • Researcher Directory
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC
Research Study

Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC

Principal Investigator
Bernhard Eigl

Overview

Disorders and Conditions
Cancers
ClinicalTrials.gov#
NCT03792841
Status
Recruiting
Start/End Dates
Jun 1, 2020
Name/Title
Lauren Hull
Phone
604-829-7655 ext.67-8112
Email Address
lauren.hull@bccancer.bc.ca
Purpose of Study

The purpose of this study is to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.

Eligibility

Visit ClinicalTrials.gov for more information.

Disclaimer

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.

Share

  • Facebook
  • Linkedin
  • Twitter
  • Instagram
  • Email

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • Instagram
  • Bluesky
  • YouTube

© 2026 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy